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a b s t r a c t
Although much progress has been achieved in the development of cancer therapies in recent decades,
problems continue to arise particularly with respect to chemotherapy due to resistance to and low
speciﬁcity of currently available drugs. Host defense peptides as effector molecules of innate immunity
represent a novel strategy for the development of alternative anticancer drug molecules. These cationic
amphipathic peptides are able to discriminate between neoplastic and non-neoplastic cells interacting
speciﬁcally with negatively charged membrane components such as phosphatidylserine (PS), sialic acid
or heparan sulfate, which differ between cancer and non-cancer cells. Furthermore, an increased num-
ber of microvilli has been found on cancer cells leading to an increase in cell surface area, which may
in turn enhance their susceptibility to anticancer peptides. Thus, part of this review will be devoted to
the differences in membrane composition of non-cancer and cancer cells with a focus on the exposure
of PS on the outer membrane. Normally, surface exposed PS triggers apoptosis, which can however be
circumvented by cancer cells by various means.
Host defense peptides, which selectively target differences between cancer and non-cancer cell mem-
branes, have excellent tumor tissue penetration and can thus reach the site of both primary tumor and
distant metastasis. Since these molecules kill their target cells rapidly and mainly by perturbing the
integrity of the plasma membrane, resistance is less likely to occur. Hence, a chapter will also describe
studies related to themolecularmechanisms ofmembrane damage aswell as alternative non-membrane
related mechanisms. In vivo studies have demonstrated that host defense peptides display anticancer
activity against a number of cancers such as e.g. leukemia, prostate, ascite and ovarian tumors, yet so far
none of these peptides has made it on the market. Nevertheless, optimization of host defense peptides
using various strategies to enhance further selectivity and serum stability is expected to yield novel anti-
cancer drugs with improved properties in respect of cancer cell toxicity as well as reduced development
of drug resistance.. Introduction
Cancer is a leading cause of death worldwide representing
bout one-eighth of all deaths (http://www.who.int/mediacentre/
actsheets/fs297/en/) and being strongly affected by demographic
hanges especially ageing of the population. In 2008, more than
2.7 million people were newly diagnosed with cancer accounting
or 7.6 million deaths, with over one quarter of the global can-
er incidences occurring in Europe. Furthermore, cancer has also
merged as a major public health problem in developing countries.
ccording to the World Health Organization new cases of cancer
Abbreviations: PS, phosphatidylserine; bLFcin, bovine lactoferricin; pHLIP, pH
low) insertion peptide.
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impairment will strongly increase with estimated death rates of up
to 11 million in the year 2030. Although in recent decades much
progress has been achieved in respect of therapies, like surgery,
chemotherapy, radiation or hormone ablation therapy, they are
not successful in more than 50% of cases (http://globocan.iarc.fr/
factsheets/populations/factsheet.asp?uno=900). Furthermore, for
those who survive the risk of reoccurrence of the disease is a major
problem. If the tumor progresses or reoccurs, chemotherapy is the
standard treatment. However, resistance as well as potential tox-
icity and the many side effects of chemotherapeutics, which are
mainly due to inadequate speciﬁcity for tumor cells, represent a
major limitation in this type of therapy. Hence, increasingly the
identiﬁcation of more speciﬁc targets generally expressed within
Open access under CC BY-NC-ND license.a certain tumor type is a major issue in anticancer research. While
considerable attention is paid to receptors of growth factors and
proteins involved in cell–cell signaling relatively little effort has
been devoted to targeting cancer cell membranes per se. Thus, this
S. Riedl et al. / Chemistry and Physics
Fig. 1. New anticancer drugs (1940s-06/2006) subdivided by source adapted from
(Newman and Cragg, 2007): (B) biological; (N) natural product; (ND) derived from
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datural product – semisynthetic modiﬁcations; (S) synthetic drug; (S/NM) syn-
hetic/natural drug mimic; (S*) made by total synthesis; (S*/NM) made by total
ynthesis/natural drug mimic; (V) vaccine.
eview will focus on a promising new approach in cancer therapy
hich is based on host defense peptides – effector molecules of
nnate immunity that speciﬁcally target cancer cells and destroy
hem within minutes, mostly by damaging cell membrane without
inding to speciﬁc receptors.
. Deﬁcits and drawbacks of conventional cancer therapies
need for novel treatment strategies
Before development of chemotherapeutics in the 1940s
Shewach and Kuchta, 2009), surgical removal of tumor tissue
as the only available treatment and can still often be success-
ully applied for localized cancers for which radiation therapy is
lso widely used to target cells by directly damaging DNA (Toﬁlon
nd Camphausen, 2009). Nevertheless, many cancer types advance
apidly, reoccur or tend to metastasize making chemotherapy the
reatment of choice (Espinosa et al., 2003). Currently used anti-
ancerdrugs aremostlybasedonalkylating agents, antimetabolites
s well as natural products and derivatives thereof. Between 1940
nd 2006, 175 new anticancer drugs were approved (Newman and
ragg, 2007). More than 50% thereof are biological (10% are usu-
lly large peptides and proteins), natural (14%) or naturally derived
roducts (28% are semisynthetic modiﬁcations) (Fig. 1). Early com-
oundswerebasedonnitrogenmustards, apowerful classof agents
hat alkylate bases of DNA (Shore, 1947), leading to cell death.
second class of chemotherapeutics, the antimetabolites, such
s aminopterin and amethopterin, do not directly interact with
NA bases but interfere with synthesis of precursors as folate and
ause mistakes during DNA replication of cancer cells (Shewach
nd Kuchta, 2009). In the 1960s, natural-product anticancer drugs
tarted to be developed such as e.g. Vinca alkaloids that inhibit
icrotubule polymerization and thereby cell division or antra-
yclines that promote cell death upon intercalation in DNA and
nhibition of replication (Chaires, 1985; Capranico et al., 1990). In
he decades that followed a large number of further chemothera-
eutics such as taxol or halychondrines and E7389 were developed
hat interfere with a variety of biological targets (Jackson et al.,
009).
.1. Side effects owing to insufﬁcient selectivityMost conventional chemotherapeutics, however, exhibit insuf-
cient selectivity against healthy mammalian cells causing
eleterious side effects (Smith et al., 2000; Cassidy and Misset,of Lipids 164 (2011) 766–781 767
2002; Kalyanaraman et al., 2002). Commonly, these agents act on
cells that divide rapidly, one of the main properties of cancer cells.
Therefore, damage can be expected in particular in rapidly dividing
normal cells, like bone marrow, gastrointestinal mucosa and hair
follicles, resulting in the most common side effects of chemother-
apy like myelosuppression (decreased production of blood cells),
mucositis (inﬂammation of the lining of the digestive tract) and
alopecia (hair loss). Newer chemotherapies, such as the use of
monoclonal antibodies (Nabholtz and Slamon, 2001), immunotox-
ins (Pastan and Kreitman, 1998) or angiogenesis inhibitors (Miller
et al., 2009), target speciﬁcdifferences between tumors andhealthy
cells and tissues, thereby exhibiting lower toxicity. However, side
effects have also been observed.
2.2. Formation of resistance
Besides toxicity, resistance to treatmentwithanticancerdrugs is
ahugeproblem.Resistancecanbe intrinsic andcan result fromindi-
vidual variations in patients and somatic cell genetic differences
in tumors (Gottesman, 2002). Furthermore, acquired resistance
has become common, by e.g. expression of one or more energy-
dependent transporters that detect and eject anticancer drugs
from cells before interaction with intracellular targets can occur,
or acquired insensitivity to drug induced apoptosis and induc-
tion of drug-detoxifying mechanism (Gottesman, 2002; Gillet and
Gottesman, 2010; Perez-Tomas, 2006). Hence, many cancer types
e.g.malignantmelanoma (Schadendorf et al., 1994;Helmbachet al.,
2001) show only slight sensitivity to anticancer drugs. Treatment
with methylating antitumor agent dacarbazine and its oral equiva-
lent temozolomide exhibits a response of only 15% (Chapman et al.,
1999; Middleton et al., 2000). In metastatic melanoma, resistance
is reported to be linked to defective apoptosis due to inhibition
of expression of a gene encoding Apaf-1, the apoptotic protease
activating factor-1 (Soengas et al., 2001). A number of multidrug-
resistant cancers have been detected and thus various approaches
including the development of drugs that engage, evade or exploit
efﬂux by ABC transporters have been described (Szakacs et al.,
2006).
Despite all the progress in the design of cancer therapy there is
still no cancer treatment that is 100%effective against disseminated
cancer (Gottesman, 2002). By contrast, the overall contribution of
curative and adjuvant cytotoxic chemotherapy to 5-year survival in
adultswasestimated tobeonly2.3% inAustralia and2.1% in theUSA
(Morganetal., 2004). Therefore, thedevelopmentofnewanticancer
drugs based on novel mode of actions with improved cancer cell
selectivity is urgently needed. Furthermore, patients suffering from
cancerwithpoor treatability likeglioblastoma, a cancerof thebrain,
do not survive longer than 1–2 years even if the cancer is detected
early and treated with surgery, chemotherapy, and radiotherapy,
(CBTRUS, 2008). Stomach, ovarian and other cancers also demand
new effective treatment.
3. Host defense peptides selectively targeting differences
between cancer and non-cancer cell membranes
In the search for novel anticancer agents, host defense peptides
have emerged as potential alternative anticancer therapeutics
offering many advantages over other therapies. Because of their
mode of action and speciﬁcity – the cell membrane being the
major target – resistance and cytotoxicity are less likely to occur
(Hoskin and Ramamoorthy, 2008; Papo and Shai, 2005; Mader and
Hoskin, 2006; Schweizer, 2009) and thus, they are also expected
to cause fewer side effects. Furthermore, these peptides mostly
damage cell membranes within minutes (Cruciani et al., 1991),
which would hinder formation of resistance (Papo and Shai, 2005).
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Table 1
Selected host defense peptides tested in in vitro studies for anticancer activity.a
Peptide/Source Sequence In vitro study
-Helical
Aureins
Southern bell frog
GLFDIIKKIAESF
(aurein 1.2)
60 cancer cell lines tested (human tumor line testing program
of the US National Cancer Institute) (∼50 active) (Rozek et al.,
2000)
BMAP-27/BMAP-28
Bovine
GRFKRFRKKFKKLFKKLSPVIPLLHLG/
GGLRSLGRKILRAWKKYGPIIVPIIRIG
Human tumor cells, leukemic cells (Risso et al., 1998)
Cecropin A
Hyalophora cecropia
Cecropin B
Chinese oak silk moth
KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK
KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL
Bladder cancer (Suttmann et al., 2008)
Leukemia (Chen et al., 1997), bladder cancer (Suttmann et al.,
2008)
Citropins
Australian blue
mountains tree frog
GLFDVIKKVASVIGGL
(Citropin 1.1)
60 human cancer cell lines (human tumor line testing program
of the US National Cancer Institute) (Doyle et al., 2003); human
histiocytic lymphoma cell line (Koszalka et al., 2011)
Epinicidin-1
Fish
GFIFHIIKGLFHAGKMIHGLV Human lung carcinoma, cervix adenocarcinoma,
hepatocellular carcinoma, ﬁbrosarcoma, histiocytic lymphoma
cells (Lin et al., 2009)
Gaegurin-6/-5
Korean wrinkled frog
FLPLLAGLAANFLPTIICKISYKC Human lung, prostate, liver, kidney and breast cancer cell lines
(Kim et al., 2003)
LL-37
Homo sapiens
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Jurkat human T leukemia cells, HeLa cells (Mader et al., 2009)
Magainins
African clawed frog
Pexiganan (MSI-78)
GIGKFLHSAKKFGKAFVGEIMNS
(Magainin 2)
GIGKFLKKAKKFGKAFVKILKK
Hematopoietic cell lines (Cruciani et al., 1991), Ehrlich ascites
tumor cells, human adenocarcinoma (Baker et al., 1993),
bladder cancer line (Lehmann et al., 2006), histiocytic
lymphoma cell line (Koszalka et al., 2011)
Melittin
Honey bee venom
GIGAVLKVLTTGLPALISWIKRKRQQ Human hepatocellular carcinoma (Wang et al., 2009a);
osteosarcoma (Chu et al., 2007); leukemic cells (Moon et al.,
2008); prostate and ovarian (Holle et al., 2003), neuroblastoma
cancer cells (Drechsler and Andrä, 2011)
NK-2
Porcine leukocytes
NKCS and derivatives
KILRGVCKKIMRTFLRRISKDILTGKK
KILRGVSKKIMRTFLRRISKDILTGKK
Human lymphocytes and seven human cancer cell lines
(Schröder-Borm et al., 2005); human neuroblastoma cancer
cells (Drechsler and Andrä, 2011)
Human prostate carcinoma cells (Manavbasi et al., 2010)
Pep27
Strep. pneumonia
MRKEFHNVLSSGQLLADKRPARDYNRK Leukemia cell lines (Lee et al., 2005)
Polybia-MPI
P. paulista
IDWKKLLDAAKQIL Human bladder cancer and prostate cancer cell line (Wang
et al., 2008)
Temporin A
Frog Rana temporaria
FLPLIGRVLSGIL Human histiocytic lymphoma cell line (Koszalka et al., 2011)
-sheet
Buforin II
Bufo bufo gargarizans
TRSSRAGLQFPVGRVHRLLRK 62 cell lines (Lee et al., 2008); human histiocytic lymphoma
cell line (Koszalka et al., 2011)
Human -defensins
Homo sapiens
Defensins
ACYCRIPACIAGERRYGTCIYQGRLWAFCC
(HNP1)
Diverse sequences
Human lung adenocarcinoma (Xu et al., 2008)
HeLa, glioma, kidney cancer, lung cancer, myeloma (Iwasaki
et al., 2009)
Gomesin
A. gomesiana
ECRRLCYKQRCVTYCRGR Breast and colon adenocarcinoma, HeLa (Rodrigues et al., 2002)
Lactoferricin B
Bovine
FKCRRWQWRMKKLGAPSITCVRRAF Neuroblastoma (Eliassen et al., 2006), melanoma, mammary
carcinoma, colorectal adenocarcinoma (Eliassen et al., 2003)
Protegrin-1
porcine
RGGRLCYCRRRFCVCVGR Human histiocytic lymphoma cell line (Koszalka et al., 2011)
Tachyplesin I
Southeast Asian
horseshoe crab
KWCFRVCYRGICYRRCR Human gastric adenocarcinoma (Shi et al., 2006); human
hepatocarcinoma cells (Li et al., 2003);
Others
PR-39
Porcine small intestine
RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP Human hepatocellular carcinoma cells (Ohtake et al., 1999)
Alloferon-1/-2
Insects
HGVSGHGOHGVHG/GVSGHGVHG Mice (IFN-production) (Chernysh et al., 2002)
Dolastatin 10 Dov-Val-Dil-Dap-Doeb Murine PS leukemia cells (Pettit et al., 1987)
se/an
H
o
w
(
m
a
h
a
p
wD. auricularia
a For a complete list of anticancer peptides check http://aps.unmc.edu/AP/databa
b Dolavaline (Dov), dolaisoleuine (Dil), dola-proine (Dap), dolaphenine (Doe).
ost defense peptides being part of the innate immune system
f many diverse species (e.g. mammals, insects, amphibians)
ere initially discovered because of their antimicrobial activity
Zasloff, 2002). Currently, the antimicrobial peptide database lists
ore than 100 natural host defense peptides with antitumor
ctivity (Wang and Wang, 2004; Wang et al., 2009b). Selected
ost defense peptides for which in vitro studies were reported
re listed in Table 1. The most intensively studied antimicrobial
eptides that also exhibit cytotoxic activity against cancer cells
ere described in detail in terms of structure, mode of action andtiC.php.
anticancer activity in a recent review by Hoskin and Ramamoorthy
(2008). These host defense peptides are characterized by low
molecular weight (in the majority of cases less than 30 amino
acids) as well as low antigenicity (Iwasaki et al., 2009) and exhibit
a predominantly cationic amphipathic structure making them
prone to interact with anionic cell membrane surfaces (Lohner and
Blondelle, 2005; Lohner, 2009). Indeed, various anionic molecules,
discussed in the following, are more abundant on the surface of
cancer cells as compared to non-cancer cells. This increased level
of negative charge seemingly accounts for the selectivity of these
S. Riedl et al. / Chemistry and Physics of Lipids 164 (2011) 766–781 769
Fig. 2. Sketchof speciﬁc characteristics of cancer cells concerningmembraneandgenetic changes. Selectivity of cationic anticancer peptides canbedrivenbydirect interaction
with anionic target molecules exposed on the cell surface such as PS. Exposure of PS (1) is related to several cell processes, which involves activation of a putative scramblase
and inactivation of a putative ATP-dependent phospholipid (PL) – translocase. Increased levels of sialic acid of glycolipids and proteins on cancer surfaces (2), normally
providing a protective shield, can also be a target for the positively charged peptides. Furthermore, changes in membrane ﬂuidity (3) and pH (4) inﬂuence susceptibility and
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cctivity of peptides, which may also be affected by the increased surface area of ca
ranslocate into the cytosolic compartment, may interact with anionic lipids of mit
ells such as e.g. inactivation of the tumor suppressor p53 (6). For details see main
embrane-active peptides towards cancer cells. In addition, one
an envisage that anticancer peptides, which translocate to the
ytosol, interact preferentially with the mitochondrial membrane
wing to its high content of negatively charged lipids such as
ardiolipin. As a consequence, the peptides may trigger apopto-
is. Of note, mitochondrial membranes of different melanoma
ariants were shown to also contain signiﬁcant amounts of phos-
hatidylserine (Schroeder and Gardiner, 1984). Furthermore, the
usceptibility of cancer and non-cancer cells towards anticancer
eptides is governed by differences in their membrane ﬂuidity
nd/or by morphological changes such as the increased number of
icrovilli found on cancer cells. Fig. 2 outlines these and additional
arameters such as acidiﬁcation of cancer cell environment that
ay be of beneﬁt in the anticancer activity of histidin-rich peptides
s well as some important processes that suppress apoptosis in
ancer cells.ells owing to the higher number of microvilli (5) present. Finally, peptides, which
dria, triggering apoptosis, a process normally blocked by several changes in tumor
3.1. Anionic phosphatidylserine exposed on the outer membrane
leaﬂet of cancer cells
Indeed, one of the major differences between cancer and non-
cancer cell-surfaces is the exposure of the negatively charged lipid
phosphatidylserine (PS) on the outer leaﬂet of the cancer cellmem-
brane, which in non-cancer cells exhibits an overall neutral charge
due to the zwitterionic phosphatidylcholine and sphingomyelin
(Bevers et al., 1996). Phosphatidylserine together with the major
part of phosphatidylethanolamine is normally located in the inner
leaﬂet of eukaryotic plasma membranes (Bevers et al., 1996). This
asymmetric distribution of the major phospholipids between the
two membrane leaﬂets is well documented (Zwaal and Schroit,
1997; Bevers et al., 1998) and assumed to be maintained by ATP-
dependent aminophospholipid translocaseactivity (Seigneuret and
Devaux, 1984) and/or abolished by a Ca2+-dependent scramblase
770 S. Riedl et al. / Chemistry and Physics
Fig. 3. PS exposure of melanoma cell lines: correlation of PS exposure with tumor
progression of melanoma cell lines expressed as multiples of PS exposure of normal
melanocytes asdeterminedbyAnnexinA5binding (SBcl-2,WM35 fromprimaryand
WM9, WM164 from metastatic lesions; error bars resulting from four independent
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ata adopted from Riedl et al. (2011a) and Zweytick et al. (2011a).
ctivity, which triggers non-speciﬁc movement of phospholipids
o both leaﬂets (Zwaal and Schroit, 1997). The loss of membrane
symmetry was demonstrated for several cancer types, reveal-
ng a promising uniform marker for cancer. Within some studies,
S exposed on the surface could even be visualized in vitro and
n vivo by speciﬁc interaction with Annexin A5 and linked to a
uorophore (Dobrzynska et al., 2007; Szachowicz-Petelska et al.,
002; Riedl et al., 2011b). Since the pioneering work of Utsugi et
l. (1991) showing that tumourigenic cells expose 3–7-fold more
S than normal keratinocytes, PS exposure has been described for
uman ovarian carcinoma (Rao et al., 1992), human gastric car-
inoma (Woehlecke et al., 2003), different melanomas (Kirszberg
t al., 2009; Cichorek et al., 2000) and leukemias (Connor et al.,
989; Schröder-Borm et al., 2005). In an extension of these stud-
es, our laboratory focused on cancer with poor outcome and
reatment efﬁcacy including metastases as well as primary cell cul-
ures and demonstrated that differently tumorigenic melanoma
ell lines expose 4–11 times more PS than melanocytes (Fig. 3),
hereby the amount of exposed PS correlated with tumor pro-
ression (Zweytick et al., 2011a; Riedl et al., 2011a). Furthermore,
e proved that not only do cell lines derived from primary lesions
nd metastasis show PS on the outer leaﬂet of the cell membrane
ut also cells from primary cancer cell cultures. The number of
ifferent cancer types used in our study including (malignant)
elanoma, a rhabdomyosarcoma, a malignant soft tissue tumor
f mesenchymal origin, prostate cancer, renal cell cancer and a
lioblastoma extended and strongly supported earlier ﬁndings,
uggesting that PS exposure is a general phenomenon of cancer
ells. In general, cells expressing PS in the outer leaﬂet of the
lasma membrane are speciﬁcally recognized by the presence of
acrophages (Fadok et al., 1992; Martin et al., 1995) and den-
ritic cells (Albert et al., 1998) triggering apoptosis. However tumor
ells, although exposing PS, circumvent apoptosis and prevent
ecognition by macrophages (Fig. 2). For example, lung and colon
ancer cells secrete elevated levels of a molecule that binds to
asL, a death activator on T-cells, and prevents them being killed.
hile melanoma inhibit expression of a gene encoding Apaf-1,
he apoptotic protease activating factor-1, certain B-cell leukemias
nd lymphomas express high levels of Bcl-2, a protein that blocks
poptotic signals (Soengas et al., 2001; Miyashita and Reed, 1993).
herefore, cationic host defense peptides, which show an excel-
ent tumor tissue penetration reaching the site of both primaryof Lipids 164 (2011) 766–781
tumor and distant metastasis (Shadidi and Sioud, 2003) and specif-
ically interact with anionic membrane lipids (Zweytick et al., 2006,
2011b; Lohner et al., 1997), represent a promising approach in the
development of novel anticancer drugs (Hoskin and Ramamoorthy,
2008; Papo and Shai, 2005; Mader and Hoskin, 2006; Schweizer,
2009). It is also of interest to note that anionic phospholipids
are also present on the surface of tumor blood vessels connected
to tumor tissue (Ran et al., 2002). The observation of negatively
charged tumor vasculature provides an additional potential tar-
get for anticancer peptides, which may be also used for imaging.
For example, selective staining of vascular endothelium of differ-
ent tumors and also tumor cells in and around regions of necrosis
was shown using 9D2, amonoclonal antibody for anionic phospho-
lipids or Annexin A5 (Ran et al., 2002). Furthermore, it is reported
that radio-labeledAnnexinA5may allow for repeated and selective
in vivo identiﬁcation of apoptotic cell death without the need for
invasive biopsy (Van de et al., 2003), which should also be applica-
ble in the imaging of tumor tissue.
3.2. Enhancement of sialic acid residues on cancer cell surface
Another source of negative charges on the surface of human
cells is represented by sialic acid residues, which are linked to
glycoproteins (e.g. mucins) and glycolipids. An overexpression of
transmembrane mucins was shown e.g. for carcinoma cells from
epithelia (Kufe, 2009; Carraway et al., 1999) and transmembrane
mucin 1 (MUC1) was overexpressed in more than 90% of breast
carcinomas and frequently in others such as ovarian, lung, colon
and pancreatic carcinoma (Bafna et al., 2010). The extent of sur-
face sialylation seems to be directly correlated with the metastatic
potential of different cancer cells exhibiting a protective func-
tion against the host immune system and facilitating migration
and invasion via modulation of adhesiveness (Wang et al., 2009a;
Litynska et al., 2001; Cazet et al., 2010). The effect of different
degrees of sialylation in terms of peptide interaction has been stud-
ied less intensively. For example, BMAP-27 and BMAP-28, host
defense peptides from the cathelicidin family, exhibited lower
activity on cancer cells when sialic acid had been cleaved off (Risso
et al., 1998) suggesting that the outside charge seems to act as an
initial interaction site for the peptides. By contrast, in a preliminary
study performed in our laboratory the activity of peptides derived
from a fragment of human lactoferricin, was unaffected by cleav-
age of sialic acid moieties of a rhabdomyosarcoma (unpublished
data), suggesting something other than sialic acid as a preferred
target for this tumor type. Summarizing, it is obvious that glyco-
sylation plays an important role in the interaction with peptides.
For more details about changes in the glycosylation pattern in can-
cer cells and impact on cell processes like cancer progression and
impairment of signaling pathways see Hoskin and Ramamoorthy
(2008).
3.3. Heparan sulfate
In addition to the above mentioned sources of negative charges
on the surface of cancer cells, the role played by proteoglycans
should also be noted (Kjellen and Lindahl, 1991). These proteins
contain highly negatively charged glycosaminoglycan side chains
mainly in the form of heparan sulfate and chondroitin sulfate
composed of linear repeats of sulfated disaccharides (Sugahara
et al., 2003; Tkachenko et al., 2005). These disaccharides contain
a high number of sulfate groups yielding highly negatively charged
molecules (Rabenstein, 2002). It has been reported for several
cancer cells that proteoglycan expression and sulfation is altered
(Jaysonet al., 1998;Kleeff et al., 1998; Safaiyanet al., 1998;Matsuda
et al., 2001; Sanderson, 2001; Aviel-Ronen et al., 2008; Nakatsura
et al., 2004). Fadnes et al. (2009) reported that chondoitrin sulfate
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ad no effect on the activity of bovine lactoferricin (bLFcin), which
owever was improved after depletion of heparan sulfate on can-
er cells and lowered upon addition of exogenous heparan sulfate.
lthough this observation seemingly implies that heparan sulfate
ay inhibit the activity of anticancer peptides, the same group
howed recently that small lytic peptides derived from bLFcin are
ot affected by heparan sulfate or even possess increased activity
n their presence (Fadnes et al., 2011).
.4. Altered membrane ﬂuidity in cancer cell membranes
Apart from changes in the pattern of the surface charge, mem-
rane ﬂuidity also appears to be altered in tumorigenic cells,
hough it is not clear if this alteration is uniform throughout all
arcinomas. The majority of studies indicate increased ﬂuidity
f the cancer cell membrane as described for lymphomas, lung
arcinomas and neural tumors (Sherbet, 1989; Sok et al., 2002;
ampanella, 1992; Rodrigues et al., 2002). By contrast, it has been
eported that cells from solid tumor tissues (e.g. hepatoma) exhibit
lower membrane ﬂuidity than their healthy counterparts (van
litterswijk, 1984). In this context it is important to note that
herbet et al. (Sherbet and Jackson, 1986) already suggested that
embrane ﬂuidity is not uniform all over the cell itself. This is
n accordance with more recent observations showing that some
reast and prostate cancer cell lines possess elevated levels of
holesterol-rich lipid rafts, raising the question if in fact only
ome parts of the cancer membrane comprise increased ﬂuid-
ty by different lateral lipid arrangement (Li et al., 2006). In the
ase of unaltered total cholesterol content, this would imply a
holesterol-depletedbulkmembraneharboringPS thatmayexhibit
igher susceptibility to peptide attack because of its increased
uidity and hence less tightly packed lipids. Interestingly, the
etastatic cascade also seems to be inﬂuenced by alterations
n membrane ﬂuidity. Thus, increased ﬂuidity was reported for
etastatic cells (Nakazawa and Iwaizumi, 1989) due to differences
n the cholesterol to phospholipid ratio (Schroeder and Gardiner,
984). According to some reports, resistance to drugs also seems to
e related to cell membrane ﬂuidity. May et al. (1988) for example
eported that vinblastine resistant leukemic cells possess 50%more
holesterol, corresponding to decreased ﬂuidity, than vinblastine
ensitive cells. This ﬁnding is supported by higher cholesterol
evels in multidrug-resistant ovarian cancer cells (Mazzoni and
rave, 1993). It is evident that knowledge of membrane ﬂuid-
ty (with cholesterol content only being one parameter alongside
egree of hydrocarbon chain saturation etc.) should be regarded as
n important physical membrane parameter that interferes with
nsertion of amphipathic peptides being facilitated in more ﬂuid
embranes.
.5. Microvilli increasing the cell surface area of cancer cells
Another important difference between cancer and non-cancer
ells is the increase in surface area of tumorigenic cells, triggered
y the increase of microvilli on these cells (Zwaal and Schroit,
997; Papo and Shai, 2005; Domagala and Koss, 1980; Chaudhary
nd Munshi, 1995). This should be beneﬁcial in the application
f membrane-active peptides since efﬁciency can be increased by
nabling the binding of a larger amount of peptides per cell (Zwaal
nd Schroit, 1997; Papo and Shai, 2005). Support for this notion
omes from a comparative study on the cytolytic effect of cecropin
on tumor cells such asKG-1 leukemia andAgs stomach carcinoma
nd non-tumor cells like ﬁbroblasts and red blood cells, which
emonstrated that the peptide was more effective on the cancer
han normal cells (Chan et al., 1998). Based on scanning electron
icroscopy data, it was suggested that this may mainly be due to
he high population of irregular microvilli on the cell surface of theof Lipids 164 (2011) 766–781 771
cancer cells and that the attraction of peptides by microvilli may
be one of the main driving forces before membranolysis can be
efﬁciently initiated.
In summary, accumulationof cationic amphipathicpeptideswill
be triggered by the presence of anionic components on the cell sur-
face as well as by the increase in cell surface owing to increased
number of microvilli, while insertion of peptides will be mainly
governed by membrane ﬂuidity, which in eukaryotic membranes
is largely regulated by its cholesterol content. Therefore, the dif-
ferences in lipid composition and morphology of cell membranes
govern the interaction with membrane-active peptide and further-
more, may also be related to the varying susceptibility of different
types of cancer cells against a certain antitumor peptide (Leuschner
and Hansel, 2004; Mader et al., 2005).
4. Mode of action of anticancer peptides
Two general mechanisms, triggering necrosis or apoptosis by
anticancer peptides as a consequence of their membrane related
mode of killing of cancer cells, have been discussed (Papo and
Shai, 2005; Bhutia and Maiti, 2008; Schweizer, 2009). Both killing
based on necrosis via cell membrane lysis and apoptosis via the
mitochondrial lytic effect seems to be dependent on the presence
of anionic lipids. As described in Section 3.1, negatively charged
PS located in the outer leaﬂet of cancer cells can represent such
a speciﬁc target, e.g. cardiolipin, a major anionic phospholipid of
the mitochondrial membrane. Other sources of negatively charged
molecules which are also exposed and often overexpressed on
non-cancer plasma membranes such as sialylated glycoproteins
or heparan sulfate proteoglycans should also be considered when
considering the activity and efﬁcacy of cationic anticancer pep-
tides. However, their inﬂuence has been studied less systematically
and seemingly contradictory effects have been reported in terms
of anticancer activity of the peptides (see Sections 3.2 and 3.3).
A major role of PS may be deduced from the selective binding of
the synthetic host defense-likemembranolytic peptide, [d]-K6L9, to
PS, which was demonstrated by co-localization of PS and peptides
on the outside of cancer cells (Papo et al., 2006). The authors thus
suggested that the selectivity of the peptide towards cancer cells
stems largely from its binding to surface exposed PS and that killing
of the cancer cells occurs via cytoplasmic membrane depolariza-
tion. Consequently, it appears that for effective disruption of the
cell membrane, peptide–lipid interaction is the crucial step which
the peptides need in order to meet the proper structural require-
ments. Thus, in order to engineer more potent antitumor peptides
in respect of efﬁcacy aswell as selectivity and thus reduced toxicity,
it is necessary to further unravel their molecular mode of action.
Furthermore, non-membrane related mechanisms have been
considered. For example, stimulation of NK cells as well as inter-
feron synthesis by the insect antimicrobial peptide alloferon
(Chernysh et al., 2002) or the transcriptional inhibitory effect of
melittin and cecropin (Winder et al., 1998) were regarded as being
probably due to an indirect mechanism, which is mediated by
the ability of the cytolytic peptide to interfere with signal trans-
duction pathways. Tachyplesin conjugated to an integrin homing
domain (Park et al., 1992; Chen et al., 2001) was further shown to
interact with the mitochondrial membranes of cancer cells and to
up-regulate members of the death receptor pathway, which sug-
gests that this peptide-conjugate also has more than one effect on
cancer cells. Therefore, Papo and Shai (2005) proposed that these
observations may imply that in addition to their being active on
their owncytolytic peptidesmayactivate or act synergisticallywith
other host defense components in order to clear tumors. Neverthe-
less, since killing takes place very rapidly it seems quite reasonable
to assume that a non-receptor mediated membranolytic killing
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echanism is responsible for the majority of anticancer peptides
erived from host defense peptides.
.1. Membrane related molecular mechanisms of cell killing
The discovery that naturally occurring antimicrobial peptides
ostly kill bacteria by damaging their cell membrane has initiated
ucheffort in thedetailed studyofpeptide–membrane interaction.
he concept of a characteristic lipid composition for a given cell
embrane is well accepted and hence the different physicochem-
cal properties of the lipids found in biological membranes allow
ost defense peptides to discriminate between e.g. bacterial, can-
er and non-cancer cellmembranes (Lohner et al., 1997; Riedl et al.,
011b; Lohner, 2001). In a simpliﬁed view, these cationic amphi-
athic peptides will exhibit a higher afﬁnity to cell membranes
hat expose negatively charged lipids on their outer membrane
eaﬂet. The molecular mechanism(s) of membrane damage mutu-
lly depends on the nature of both peptides and membrane lipids
Sevcsik et al., 2008).
Severalmodels (Fig. 4) have been suggested to explain their bio-
ogical activity (for reviews see e.g. Lohner and Blondelle, 2005;
ohner, 2009; Bechinger, 2009; Wimley and Hristova, 2011). The
ost frequently discussed mode of action includes the formation
f toroidal pores (Matsuzaki et al., 1996; Ludtke et al., 1996) and
he carpet model (Shai, 2002). In the toroidal pore model peptides,
ogether with the lipid, assemble into a supra-molecular arrange-
ent of high curvature forming a water-ﬁlled pore. Although a
umber of molecules including -helical and -sheet type pep-
ides have been shown to adopt such a pore under the given
xperimental conditions (Huang, 2006), there is little evidence
hat the majority of these peptides act in vivo via transmem-
rane pores (Wimley, 2010). The carpet model is most commonly
ited when explaining membrane disintegration by a non-pore
odel. In this model, the amphipathic peptides accumulate at
he membrane being aligned parallel to the bilayer surface. Once
his “peptide carpet” becomes too dense, membrane permeabi-
ization occurs via destabilization of the membrane bilayer (Shai,
002). Thereby, at the molecular level different scenarios may
pply, which were recently summarized in an excellent review by
imley and Hristova (2011). Brieﬂy explained, membrane perme-
bilization has been proposed as being due to (a) peptide induced
lustering or phase separation of lipids creating defects at the
eptide-rich andpeptide-poor domains (Lohner, 2009; Epand et al.,
010; Epand and Epand, 2009, 2011; Lohner and Prenner, 1999;
weytick et al., 2011b), (b) the sinking raft model, which allows
formal thermodynamic analysis to predict membrane perturba-
ion (Pokorny and Almeida, 2004; Pokorny et al., 2008; Gregory
t al., 2008; Almeida and Pokorny, 2009), (c) disruption of the
ormally strict segregation of polar and non-polar groups of the
ipidsdrivenby thepartitioningof an imperfectly amphipathicpep-
ide into the bilayer interface (Rathinakumar and Wimley, 2008,
010) or (d) a detergent-like action in particular at high peptide
oncentration (Hristova et al., 1997; Bechinger and Lohner, 2006;
stolaza et al., 1993). Furthermore, a complex generic phase dia-
ram has recently been developed rationalizing the membrane
nteractions of cationic amphipathic peptides by their molecu-
ar shape to explain in a more general sense the mode of action
f these cationic amphipathic peptides (Bechinger and Lohner,
006; Bechinger, 2009). Besides electrostatic interactions, molec-
lar properties of lipids such as their molecular shape and being
elated to the spontaneous curvature are known to play a signif-
cant role for the aggregation state of lipids (Israelachvili et al.,
980; Marsh, 1996; Bechinger, 2009) and, thus, also to affect inter-
ctions of these assemblieswithmembrane-active peptides. In fact
n terms of structural membrane changes, insertion of antimicro-
ial peptide molecules, some of them also exhibiting antitumorof Lipids 164 (2011) 766–781
activity such as NK-2 (Schröder-Borm et al., 2005) or lactoferricin
derivatives (Riedl et al., 2011b), promoted the formationof inverted
hexagonal or bi-continuous cubic phases in membrane mimetic
systems (Staudegger et al., 2000;Willumeit et al., 2005;Hickel et al.,
2008; Zweytick et al., 2008, 2011b).
Furthermore, solid tumors are discussed as exhibiting an acidic
extracellular environment (for a review see Grifﬁths, 1991). This
acidiﬁcation seems to be a consequence of lactic acid accumulation,
which is produced during aerobic and anaerobic glycolysis and,
due to inadequate vasculature in growing tumors, its insufﬁcient
removal. However, lactic acid accumulationdoesnot seem tobe the
only reason for the acidiﬁcation of the extracellular environment
of tumors. Newell et al. (1993) reported that glycolysis-deﬁcient
cells are also more acidic than cells from normal tissues with-
out accumulating lactic acid above serum levels. In any case, an
acidic tumor environment might be a useful “activation” switch for
anticancer peptides comprised of amino acids like histidine, which
are only positively charged and thus active at low pH (Makovitzki
et al., 2009). Such an approach was reported for the synthetic
host defense-like lytic peptide [d]-K6L9, where the lysine residues
were exchanged byhistidine, resulting in reduced systemic toxicity
compared to the parent peptide. It was suggested that the pH-
dependent activity and lytic mode of action of the His-rich peptide,
in hindering development of resistance, will make them potential
candidates for treatment of solid tumors. In fact, intra-tumor and
systemic inoculation of ([d]-H6L9) signiﬁcantly reduced the 22RV1
prostate cancer tumor size in a xenograft mice model (Makovitzki
et al., 2009).
In the context of taking advantage of the acidic environ-
ment of solid tumors it is worthwhile reporting on pHLIP (pH
(Low) Insertion Peptide), a peptide derived from the C-helix of
bacteriorhodopsin, although this peptide neither displays a mem-
branolyticmechanismnor is it derived fromahost defense peptide.
pHLIP shows interesting pH-sensitive properties in that it only
forms a transmembrane helix in the acidic environment of solid
tumors, whereas at neutral or high pH it is in equilibrium between
an unstructured form and bound to the surface of a lipid bilayer
(Hunt et al., 1997; Reshetnyak et al., 2007). pHLIP itself does not
exhibit direct toxicity to cells (Reshetnyak et al., 2006) or mice
(Andreev et al., 2007) at concentrations below50M, however, the
peptide in its helical form possesses useful drug delivery efﬁciency
facilitating translocation of cell-impermeable polar molecules into
the cytoplasm (Reshetnyak et al., 2006, 2007; Andreev et al., 2007;
Zoonens et al., 2008; Thévenin et al., 2009). One example of efﬁ-
cient drug delivery into cancer cells through translocation with
pHLIP is phalloidin toxin, which inhibits cancer cell proliferation
after cleavage from pHLIP inside the cells (An et al., 2010).
4.2. Non-membrane related mechanisms
Here, we brieﬂy summarize some mechanisms, which do not
involve permeabilization/disruption of plasma or mitochondrial
membranes in cancer cells. There is growing evidence that the
antimicrobial activity of host defense peptides is not solely related
to cellmembrane damage but some act caused by immunomodula-
tory effects (Hancock and Sahl, 2006; Easton et al., 2009;Wieczorek
et al., 2010). Little knowledge is so far available as to whether this
may also be the case for the antitumor activity of these cationic
amphipathic peptides. In particular in the case of cancers where
the immune response is often diminished or strongly suppressed,
it was suggested that cancer therapies might be supported by the
simultaneous administration of immunoadjuvants, which activate
both an innate and acquired immune system response (Dredge
et al., 2002). Although many small peptides of microbial origin
possess a non-speciﬁc immunostimulatory response (for a review
see Schweizer, 2009), reports on an immunomodulatory effect of
S. Riedl et al. / Chemistry and Physics of Lipids 164 (2011) 766–781 773
Fig. 4. Mode of action of membrane-active host defense peptides: boundaries of the schematic phase diagram of amphipathic peptide/phospholipid aggregates are given as a
function of the concentration of membrane-associated peptide and the composition of the membrane from mixtures of cylindrical (phosphatidylserine, phosphatidylcholine)
and truncated inverted cone lipids (cardiolipin, phosphatidylethanolamine); modiﬁed from Bechinger (2009). Membrane association of the cationic peptides is strongly
increased in the presence of anionic phospholipids such as PS or cardiolipin. In the presence of cholesterol, an abundant membrane component in mammalian cells, the
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ost defense peptides in cancer cells are rare. One example are
lloferons, histidine-rich peptides from insects shown to stimu-
ate natural killer cells of human peripheral blood lymphocytes
nd to induce synthesis of interferon in mice models (Chernysh
t al., 2002). This cytokine-like modulating property resulted in
ntitumor resistance.
Speciﬁc targets have so far only been reported for a few anti-
ancer peptides. PR-39, a peptide of the cathelicidin family which
s rich in proline and arginine residues, can translocate into the
ytosolic compartment of cells without permeabilizing the plasma
embranewhere it interactswithproteins containingSH3-binding
otifs (Chan and Gallo, 1998; Tanaka et al., 2001). Experiments
sing derivatives of PR-39 indicated that the N-terminal arginine
s crucial for binding to the SH3-domain and subsequent induc-
ion of syndecan-1 production (Chan et al., 2001). Indeed, elevated
evels of syndecan-1 were observed in treatment of human hepa-
ocellular carcinoma cells with either PR-39 or upon transfection
f this cell line with the PR-39 gene (Ohtake et al., 1999). Expres-
ion of syndecan-1 has been related to inhibition of cell invasion
Liebersbach and Sanderson, 1994) and thus it was suggested that
his linear cationic peptide may suppress the invasive activity of
hese cancer cells therefore preventing metastasis (Ohtake et al.,
999). Another target of many anticancer drugs is tubulin, which
as also shown to be the site of action for linear peptides derived
rom the host defense-like peptide dolastatin 10 (US Pat. No.
,816,444) or dolastatin 15 (EP-A-398558) (Simmons et al., 2005).
hereby, the mechanism of action, as for all antitumor tubulin lig-
nds, involves theperturbationofmicrotubuledynamicsduring the
2/M phase of cell division and subsequent entry into apoptosis
Davis et al., 1999).
Finally, a speciﬁc case was reported for bee venom melittin,
hich preferentially counter-selects mammalian cells with the
verexpressed ras oncogene,where it acts through hyperactivation
f phospholipase A2 (Sharma, 1992). It should be noted, however,
hat melittin is also known for its toxicity to mammalian cells (e.g.olecular mechanisms of bilayer perturbation are schematically shown (for details
(Habermann and Jentsch, 1967)). In fact, for in vivo studies a melit-
tin/avidin conjugate was used, which did not exert its anticancer
activity by membranolysis but by targeting cancer cells with high
matrix metalloproteinase 2 (Holle et al., 2003) as described in Sec-
tion 5.2.
5. In vivo studies of anticancer peptides
Based on successful in vitro experiments, a number of pep-
tides have also been tested in vivo to explore their therapeutic
potential (Table 2). In addition to the administration of anticancer
peptides per se, strategies have been developed that may improve
pharmacokinetics and/or selectivity and hence reduce toxicity.
This includes the application of vector-mediated delivery of genes
encoding membranolytic peptides and the use of homing domains
transporting the anticancer peptides into the cytosolic compart-
ment of cancer cells. Some of the respective in vivo studies are
brieﬂy described below.
5.1. Anticancer activity of peptides related to membrane damage
Magainins, originally isolated from the skin of the African
clawed frog, Xenopus laevis (Zasloff, 1987), were among the ﬁrst
peptides to be tested for their in vivo anticancer activity. Maga-
inin 2 was shown to exhibit an amphiphilic-helical structure that
facilitates the formation of ion-permeable pores in membranes,
consequently inducing depolarization and cytolysis (Cruciani et al.,
1991). Baker et al. (1993) demonstrated that magainin analogues
were able to elevate the survival level of animals with ascites-
producing tumors. Furthermore, magainin 2 has been tested for
local treatment in a subcutaneous xenograft model of melanoma
in nude mice, where it completely eliminated the tumor with only
minimal damage to surrounding tissue (Soballe et al., 1995).
Another prominent member of anticancer peptides is bovine
lactoferricin (Gifford et al., 2005), which is generated from
774 S. Riedl et al. / Chemistry and Physics of Lipids 164 (2011) 766–781
Table 2
In vivo studies of anticancer peptides and proposed mode of action.
Peptidea Mode of action Type of tumor
-Helical
Magainin and analogues Lytic Murine ascites tumors (Baker et al., 1993); melanoma xenograft in nude mice (Soballe
et al., 1995)
Melittin/avidin-conjugate Lytic Melanoma in mice (Holle et al., 2003)
Polybia-MPI/MPI-1 Necrosis Sarcoma xenograft tumors in mice (Zhang et al., 2010)
-sheet
Human -defensins Apoptosis Human lung adenocarcinoma xenograft in nude mice (Xu et al., 2008)
Gomesin Necrosis Murine melanoma (Rodrigues et al., 2008)
Lactoferricin B Necrosis/Apoptosis Fibrosarcoma, melanoma, colon carcinoma (Eliassen et al., 2002); Xenografting of
SH-SY-5Y cells in nude rats (Eliassen et al., 2006); inhibition of metastasis of melanoma
and lymphoma in mice (Yoo et al., 1997)
RGD-tachyplesin Apoptosis Melanoma mice (Chen et al., 2001)
Others
Dolastatin 10 Anti-proliferative Indolent lymphoma, Waldenstrom’s macroglobulinemia and chronic lymphocytic
leukemia (Simmons et al., 2005)
Synthetic
[d]-K6L9 Necrosis Breast cancer in SCID/NCr mice (Papo et al., 2006)
[d]-H6L9 Lytic 22RV1 prostate cancer in mice (Makovitzki et al., 2009)
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actoferrin through pepsin cleavage. Unlike magainins, bLFcin pos-
esses an acyclic twisted antiparallel -sheet structure due to a
isulﬁde bridge between two cysteine residues (Vogel et al., 2002).
ystematic studies on bLFcin derivatives revealed some param-
ters of importance for antitumor activity such as the need for
igh net positive charge (+7 as compared to +4 for antimicrobial
ctivity) and clear cationic and hydrophobic sectors (amphipathic-
ty) (Yang et al., 2004, 2003). Furthermore, the requirement of a
tabilized secondary structure may be deduced from the higher
ctivity of the cyclic peptide (Eliassen et al., 2002), which showed a
learer partitioning of the cationic and hydrophobic faces (Nguyen
t al., 2005). As this property is less important for antimicrobial
ctivity, it was suggested that it indicates a constraint for the pep-
ide to traverse mammalian membranes (Gifford et al., 2005). Yoo
t al. (1997) demonstrated that the peptide inhibits liver and lung
etastasis in mice. Additionally, bLFcin showed antiangiogenic
ctivity leading to suppressionof tumorgrowth. In vivo studieswith
LFcin on ﬁbrosarcoma, melanoma and colon carcinoma tumors
evealed massive necrosis of the tumor tissue after exposure to the
eptide (Eliassen et al., 2002). Eliassen et al. (2006) also showed
hat bLFcin signiﬁcantly inhibits tumor growth of neuroblastoma
enografts in nude rats. Clariﬁcation of the mechanism revealed
hat bLFcin induces apoptosis in human tumor cells through a
athway mediated by production of the intracellular ROS and acti-
ation of Ca2+/Mg2+-dependent endonucleases (Yoo et al., 1997),
hichwaspartially conﬁrmedby studies carried out byMader et al.
2005), who also documented the mitochondrial pathway of apo-
tosis for bLFcin. Other studies reported that induction of apoptotic
r necrotic cell death was dependent on the concentration of the
eptide (Onishi et al., 2008; Eliassen et al., 2006). Recently, it was
hown that in vitro treatment with bLFcin killed Raji and Ramos
uman B-lymphoma cells via a caspase-independent apoptotic
athway being more efﬁcient at low serum concentration of the
eptide (Furlong et al., 2010).Notably, in thepresenceof exogenous
ovine serum albumin the activity was inhibited, which suggests
artial neutralization of the cationic peptide by anionic serumcom-
onents as described earlier for the inhibition of the tumoricidal
ctivity of amphiphilic alpha helical peptides (Peck-Miller et al.,
993). Nevertheless, immune-deﬁcient SCID/beige mice exhibited
xtended survival using systemic administration of bLFcin under-
ining the potential of this peptide for further development as novel
nticancer agent.Gomesin (Gm), an antimicrobial peptide isolated from the
hemocytes of the unchallenged Brazilian spider Acanthoscurria
gomesiana, also exhibits anticancer activity (Silva et al., 2000). This
cationic peptide adopts a hairpin-like two-stranded antiparallel
-sheet structure, which is maintained by two internal disulﬁde
bridges (Mandard et al., 2002). Topical treatment of subcutaneous
murine melanoma with gomesin signiﬁcantly retarded tumor
growth and increased the number of animals with tumors below
a critical size (Rodrigues et al., 2008). Importantly, Gm did not
exhibit any toxic effect on the peripheral healthy skin of mice after
repeated applications of the peptide. Gm does not kill tumor cells
through apoptosis but rather through induction ofmorphologic cell
alterations with increased granularity, loss of cytoplasmic content
by membrane permeabilization, and partial collapse of the proton
gradient (Rodrigues et al., 2008).
Polybia-MPI (MPI) is an anticancer peptide derived from the
venom of social wasp Polybia paulista. In order to improve the
activity and stability of MPI, the C-terminal amide of the peptide
was replaced by a thioamide group (MPI-1) (Zhang et al., 2010).
Indeed, MPI-1 is more efﬁcient in suppresssing tumor growth of
sarcoma xenograft in mice than MPI, which was attributed to its
higher serum stability. However, the modiﬁcation did not affect
the cytotoxic behavior of the peptide. In vitro studies provide evi-
dence of killing caused by necrosis as a result of acute cell injury,
swelling and bursting via disruption of themembrane or formation
of transmembrane pores (Wang et al., 2009c).
An alternative approach for in vivo use of membranolytic pep-
tides to maintain therapeutic levels and reduce cytotoxicity was
suggested by Winder et al. (1998) and involving the introduction
of vector-mediated delivery of genes encoding cecropin or melittin
into a human bladder carcinoma derived cell line (Winder et al.,
1998). The resultant cell clones were analyzed for tumorigenic-
ity in nude mice showing that expression of cecropin resulted
in either a complete loss of tumorigenicity in some clones or
reduced tumorigenicityasmeasuredby latencyof tumor formation.
Similarly, a plasmid that expressed secretable human -defensin-
1, also known as the human neutrophil peptide-1 (HNP1) was
used in gene therapy of a human lung adenocarcinoma xenograft
in nude mice (Xu et al., 2008). In this study, Xu et al. (2008)
showed that HNP1 can be intracellularily expressed in tumor cells
resulting in signiﬁcant inhibition of tumor growth by induction of
apoptosis.
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.2. Anticancer agents based on anticancer peptide-conjugates
Melittin, extracted from the European honey bee Apis mellifera,
s a mostly -helical peptide assumed to induce cell lysis by pore
ormation (Tosteson and Tosteson, 1981; Matsuzaki et al., 1997).
ince melittin is highly toxic to red blood cells and untransformed
ells, a melittin/avidin conjugate was designed to gain an inactive
eptide towards healthy cells as it speciﬁcally targets cancer cells
ith high matrix metalloproteinase 2 (MMP2) activity (Holle et al.,
003). MMP2 is known to be overexpressed in several cancers and
umor microvascular endothelial cells and has the ability to reacti-
ate peptide activity by cleavage of the conjugate at the tumor site.
nvivo studies showed that the sizeofB16 tumors inmicedecreased
igniﬁcantly after treatment with the melittin/avidin conjugate.
ctivity of the conjugate most probably arises from its ability to
arget tumor vasculature since the level of cell lysis in cultured cells
as relatively low (Holle et al., 2003).
Tachyplesin, apeptide isolated fromhemocytesof thehorseshoe
rab (Tachypleus tridentatus), exhibits a structure with exposed
asic amino acids on the peptide surface (Nakamura et al., 1988),
hich enables binding to anionic phospholipids (Park et al., 1992;
atsu et al., 1993). The peptidewas shown to have anticancer activ-
ty in vivo in a B16 mouse model (Chen et al., 2001). In this study,
synthetic tachyplesin was conjugated to the integrin homing
omain RGB, which enables internalization of the peptide.
.3. Anti-proliferative peptides
Dolastatin 10 (US Pat. No. 4,816,444) derived from the family
f dolastatins, a peptide isolated from the marine shell-less mol-
usk Dolabela auricularia, completed Phase II trial against indolent
ymphoma, Waldenstrom’s macroglobulinemia and chronic lym-
hocytic leukemia in 2000 (Simmons et al., 2005). At the time of
iscovery it was shown to be the most potent anti-proliferative
gent against murine PS leukemia cells (Pettit et al., 1987). Even-
ually, the peptide had to be dropped from clinical trials because
f moderate peripheral neuropathy in 40% of patients. Therefore,
erivatives of dolastatin 10, like TZT-1027 (Soblidotin) (Miyazaki
t al., 1995) or of dolastatin 15 (antimitotic), like ILX-651 (Syn-
hadotin) (Ebbinghaus et al., 2004), which show reduced toxicity
ut yet potent antitumor activity have been further explored in
linical studies.
. Challenges for the development of host defense peptides
s novel anticancer agents
Interestingly, despite numerous successful in vivo studies none
f themembrane-active host defense peptides has so farmade it on
o themarket. Theremaybe several reasons for this and their devel-
pmentasnovel anticancer agentmaypredominantlybehampered
y the poor bioavailability and potential toxicity of such peptides
Hancock and Sahl, 2006). Peptide degradation in serum owing to
he presence of proteases is a major obstacle, which besides unspe-
iﬁc binding to serum components also limits the half time of these
olecules in serum. In order to improve the pharmacodynamic
roperties, different strategiesmay be applied to achieve enhanced
ell speciﬁcity and serum stability.
.1. Enhancing selectivity to further reduce cytotoxicity
Notall hostdefensepeptides showingantitumoractivityare suf-
ciently selective against cancer cells. Accordingly, a more detailed
nowledge of their structure–activity relationship is required in
rder to understand the molecular peptide parameters for the
esign of promising novel antitumor agents. As outlined above,
ost defense peptides exhibit great structural diversity yet shareof Lipids 164 (2011) 766–781 775
some common features. They are typically 10–40 amino acids long
and positively charged (net charge of +2 to +9). While differing in
the percentage of hydrophobic residues, these peptides share an
amphiphilic character, i.e. they have the ability to adopt a struc-
ture inwhich hydrophobic and polar/charged residues are spatially
organized indiscrete sectorsof themolecule.Althoughhostdefense
peptides belong to different structural classes, they often exhibit an
intrinsic ﬂexibility and structural adaptability, which are thought
to be responsible for differentmodes of interactionwithmembrane
bilayers (Joanne et al., 2009). Thus net charge, amphipathicity,
hydrophobicity, and structural propensity are among the most
important physicochemical and structural parameters that govern
the ability of these peptides to interact with cell membranes. A
statistical analysis of the antitumor peptides listed in the Antimi-
crobial Peptide Data Base (Wang and Wang, 2004; Wang et al.,
2009b) in terms of secondary structure, length of the peptide, dis-
tribution of charged and hydrophobic amino acid residues and
determination of hydrophobicity expressed as transfer free energy
of peptides from water to n-octanol (Gwoct) (Wimley et al., 1996)
show that these parameters can vary within a wide range (Fig. 5).
It is interesting to note that there is still a large fraction of peptides
with unknown structure (∼39%) being comparable to the fraction
of peptides with -helical structure (∼34%), which seems to be the
predominant one. However, as can be deduced from Tables 1 and 2
there have been not less peptides tested successfully in in vitro and
in vivo studies, which exhibit a -sheet structure, although these
peptides accountonly for∼2%of the total antitumorpeptides listed.
Pair correlations betweenpeptide length and charge aswell as pep-
tide length and hydrophobicity indicate again that even for a given
peptide length theseparameters canvarywidelybeingmoreappar-
ent for the distribution of the net charge (Fig. 6). For a meaningful
interpretation of these data one would also need to consider the
antitumor activity and cell speciﬁcity of the peptides. However,
this cannot be performedon this set of data, as the peptides listed in
the Antimicrobial Peptide Data Base (Wang andWang, 2004;Wang
et al., 2009b) were tested against different cancer cells and healthy
mammalian cells using also different protocols. But a cluster anal-
ysis of a database of 158 amphipathic -helical peptides, from
which the activity spectrum was determined, revealed structural
characteristics of anticancer peptides (Dennison et al., 2010). This
databasewas constructedusingdata presentedbyOwen (USPatent
6,875,744), and contained 14 peptides, which showed selectivity
for cancer cell lines only, 123 peptides showing cytotoxicity also to
non-cancer cells and 21 inactive peptides. Three-dimensional clus-
tering techniqueswereused togroup thesepeptideswith respect to
similarity in net positive charge, hydrophobicity and hydrophobic
moment producing 21 clusters. The observation that the inac-
tive peptides were found across seven clusters highlights the fact
that these three parameters alone cannot be used as predictors of
activity. However, as hydrophobicity of peptides is important for
membrane penetration, an extended hydrophobic moment plot
analysis was also performed. Although peptides with arc sizes
>270◦ appeared to be less toxic, statistical analysis was unable to
establish a direct correlation between arc size and toxicity. Fur-
thermore, using this approach it was predicted that over 50% of
the active peptides would be surface active. This suggests that
amphiphilicity is a key driver of the membrane interactions for
these peptides. Thereby, peptides showing cancer cell speciﬁcity
fell within a narrow range of amphiphilicity of 0.53–0.78 and had
no tilted helical peptide structure, which within the analysis was
more commonly found for peptides being toxic to both cancer and
non-cancer cells. Sucha tilted structurehas alreadybeenpreviously
associated with relatively non-speciﬁc means of cell membrane
lysis (Hoskin and Ramamoorthy, 2008). This cluster analysis in
conjunction with an earlier study carried out by the same group
(Dennison et al., 2006) suggests that the interplay of a range of
776 S. Riedl et al. / Chemistry and Physics of Lipids 164 (2011) 766–781
Fig. 5. Characteristics of anticancer peptides: (A) peptide length; (B) net charge; (C) hydrophobic content (% hydrophobic amino acids;
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aking into account the contribution of both endgroups (COO− and NH3+), in ca
espectively (http://blanco.biomol.uci.edu/mpex/) (Wimley et al., 1996), n.c., not ca
hysicochemical characteristics rather than any single overriding
actor determines the biological activity of these peptides. Further-
ore, to add to the complexity of the systemonemust bear inmind
hat the lipid composition of the target membrane should not be
eglected as it in turn strongly affects the penetration behavior of
eptides. Therefore, application of newly developed technologies
or high-throughput screening as recently described in regard to
ntimicrobial peptides (Blondelle and Lohner, 2010) may be ben-
ﬁcial in unraveling the molecular parameters making anticancer
eptides more suitable for clinical use, i.e. exhibiting high speci-
city and activity, low susceptibility to proteolysis and reduced
oxicity..2. Improving serum stability
The in vivo potency of antitumor peptides is often hindered by
roteolysis of the peptides, which reduces their half time in serumxpressed as transfer free energy of peptides from water to n-octanol (Gwoct)
-amidation or N-acetylation Gwoct decreases by 3.6 kcal/mol and 2.3 kcal/mol,
ed for peptides >70 amino acids; (E) structural characteristics.
and hence bioavailability. One strategy used to overcome this prob-
lem is the application of vector-mediated delivery of genes that
encode the active anticancer peptide (Winder et al., 1998) as out-
lined in Section 5.1. Another simple but efﬁcient modiﬁcation is
the incorporation of d-amino acids or the replacement of all nat-
urally occurring l-amino acids by its diastereomer (Papo and Shai,
2005). Early studies on magainin 2 and its all d-amino acid ana-
logueMSI-238 demonstrated the feasibility of this approach (Baker
et al., 1993). Both peptides were found to be active against P388
leukemia, S180 ascites and spontaneous ovarian tumor of mice
upon intra-peritoneal injection of peptides, but with the all-D pep-
tide showing signiﬁcantly higher in vitro activity than the all-L
peptide (Baker et al., 1993). A series of studies were initiated using
systematically de novo-designed antimicrobial peptides composed
of both d- and l-amino acids mimicking the lytic activity of host
defense peptides (Papo and Shai, 2003). The resulting diastere-
omeric peptides lost their cytotoxic effect against normal cells but
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Fig. 6. Pair correlations between peptide length and net charge (A) and hydrophobicity (B), respectively, for antitumor peptides listed in the Antimicrobial Peptide Database,
APD2 (Wang et al., 2009b) excluding the three peptides >70 amino acids for which noGwoct can be calculated. The secondary structure of the individual peptides is indicated
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reserved anticancer activity with reduced serum inactivation and
nzymatic degradation in vivo. For instance, one speciﬁc diastere-
mer composed of 15 amino acids ([d]-K6L9) showed selectivity
o primary and metastatic tumors in human prostate and breast
enografts when administered systemically (Papo et al., 2004,
006). A histopathological evaluation revealed that the diastere-
mer did not cause any damage to organs of mice emphasizing
he potential for such peptides to be developed for therapeutic
pplication.
. Perspectives
Cancer treatmentwith chemotherapeutics still hasmany severe
ide effects and can induce drug resistance thus adversely affect-
ng their successful use. Therefore, novel therapeutic approaches
ith improved cancer cell selectivity and thus reduced toxicity as
ell as hindered resistance development are urgently needed as
as been observed for membrane-active host defense peptides in
number of in vivo studies (see Section 5). It is also advantageous
hat they have excellent tumor tissue penetration, which enables
hem not only to reach primary but also metastatic tumor sites.
owever, despite the wealth of information the molecular basis
or selective targeting of cancer cells and the mechanism of cell
illing by host defense peptides remain questions to be solved.
ince there is a wide variety of host defense peptides yet many
f them do not possess sufﬁcient antitumor activity, optimization
f peptides including innovative types of peptide modiﬁcation to
ne-tune their selective interaction with their target cell mem-
rane together with a profound knowledge of their characteristic
ipid composition are needed in order to attain a highly active and
peciﬁc peptide. Biophysical studies considering the peptides as
ell as membrane characteristics will provide new insights for
he rationale design of anticancer peptides. The progress may be
acilitated by recent advances in high-throughput screening tech-
iques that can also be implemented in academic laboratories.
ased on such knowledge, the ﬁeld of peptidomimetics may offer
lternative means for the development of anticancer drugs with
ptimized pharmacodynamic proﬁles. In conclusion, these strate-
ies are expected to yield novel anticancer drugs with improved
roperties with respect to selectivity and thus reduced toxicity, as
ell as to hindered development of drug resistance. These pep-
ides may also be used in combination with chemotherapeutics as
ome peptides have shown synergy with classical chemotherapy, unknown; ×, others.
(Papo and Shai, 2005). Achieving this goal would represent a major
advancement in cancer treatment.
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